There are 2789 resources available
442P - A phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients. GEMCAD 16-02 (AVEVAC trial)
Presenter: Marta Español-Rego
Session: ePoster Display
443P - EMERGE: A phase II trial assessing the efficacy of domatinostat plus avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal cancers – phase IIA dose finding
Presenter: Elizabeth Cartwright
Session: ePoster Display
444P - Prevalence of NTRK1/2/3 fusions in dMMR/MSI metastatic colorectal cancer
Presenter: Magali Svrcek
Session: ePoster Display
445P - Tumor load surrogates as major prognostic factors in BRAF-V600E mutated (mt) colorectal (CRC) patients treated with BRAF inhibitor+antiEGFR +/- MEK inhibitor
Presenter: Francisco Javier Ros Montana
Session: ePoster Display
446P - Bayesian monitoring of lapatinib (L) plus trastuzumab (T) treatment of HER2 positive metastatic colorectal cancer (mCRC): An observational cohort study
Presenter: Alessio Amatu
Session: ePoster Display
447P - The prognostic factors in early stage BRAF mutant colorectal cancer: Experience from a large volume UK tertiary centre
Presenter: Justin Mencel
Session: ePoster Display
448P - Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practice
Presenter: Mikhail Fedyanin
Session: ePoster Display
449P - Homologous recombination repair gene mutations predict the efficacy of immune checkpoint inhibitors therapy in colorectal cancer
Presenter: Yan Lin
Session: ePoster Display
450P - Efficacy and safety of pyrotinib-based therapy in HER2-positive metastatic colorectal and gastric cancer: A retrospective study
Presenter: qian Li
Session: ePoster Display